Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.
Yokokawa T, Suzuki K, Tsuji D, Hosonaga M, Kobayashi K, Kawakami K, Kawazoe H, Nakamura T, Suzuki W, Sugisaki T, Aoyama T, Hashimoto K, Hatori M, Tomomatsu T, Inoue A, Azuma K, Asano M, Takano T, Ohno S, Yamaguchi M. Yokokawa T, et al. Among authors: tsuji d. Cancer Med. 2023 Sep;12(18):18745-18754. doi: 10.1002/cam4.6494. Epub 2023 Sep 7. Cancer Med. 2023. PMID: 37676079 Free PMC article.
Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R, Hayashi H, Inoue K, Nakamichi H, Shiokawa M, Itoh K. Ikeda M, et al. Among authors: tsuji d. Drug Metab Pharmacokinet. 2015 Apr;30(2):149-53. doi: 10.1016/j.dmpk.2014.09.009. Epub 2014 Nov 4. Drug Metab Pharmacokinet. 2015. PMID: 25989890
Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K. Tsuji D, et al. Support Care Cancer. 2019 Mar;27(3):1139-1147. doi: 10.1007/s00520-018-4403-y. Epub 2018 Aug 10. Support Care Cancer. 2019. PMID: 30094732 Clinical Trial.
Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).
Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T. Shimizu H, et al. Among authors: tsuji d. J Pharm Health Care Sci. 2018 Dec 10;4:31. doi: 10.1186/s40780-018-0128-9. eCollection 2018. J Pharm Health Care Sci. 2018. PMID: 30555710 Free PMC article.
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Tsuji D, Nakagaki S, Yonezawa I, Suzuki K, Yokokawa T, Kawasaki Y, Yamaguchi T, Kawaguchi T, Hatori M, Matsumoto T, Sakata Y, Yamamoto K, Nishimura T, Kogure Y, Hayashi T, Osawa M, Itoh K, Watanabe M. Tsuji D, et al. Invest New Drugs. 2024 Feb;42(1):44-52. doi: 10.1007/s10637-023-01414-y. Epub 2023 Dec 6. Invest New Drugs. 2024. PMID: 38055127 Clinical Trial.
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, Osada-Tsuchiya M, Otake A, Nakao M, Yano T, Arakawa Y, Matsuo K, Ohashi Y, Sakata Y, Kogure Y, Tamaki S, Wada A, Taki Y, Sasahira N, Ishii H, Yamaguchi M, Itoh K. Hatori M, et al. Among authors: tsuji d. Cancer. 2024 Apr 29. doi: 10.1002/cncr.35343. Online ahead of print. Cancer. 2024. PMID: 38682652
188 results